SCHEMBL3955233

SCHEMBL3955233

Nc1n[nH]c2c(F)c(-c3ccc(NC(=O)Nc4ccccc4)cc3)ccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.58
KIT P10721 18/20 0.58
FLT3 P36888 17/20 0.58
CSF1R P07333 6/20 0.58
FLT1 P17948 6/20 0.58
FLT4 P35916 6/20 0.58
LYN P07948 5/20 0.58
BLK P51451 5/20 0.58
LCK P06239 5/20 0.58
PLK4 O00444 4/20 0.58
AURKA O14965 4/20 0.58
ROCK2 O75116 4/20 0.58
RPS6KA3 P51812 4/20 0.58
NTRK2 Q16620 4/20 0.58
MARK2 Q7KZI7 4/20 0.58
AURKB Q96GD4 4/20 0.58
CHEK2 O96017 3/20 0.58
SRC P12931 3/20 0.58
FGFR1 P11362 3/20 0.58
RPS6KB1 P23443 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3959575 0.90 KDR (0.65) KDRKITFLT3CSF1RFLT1
SCHEMBL5226811 0.89 KDR (0.48) KDRKITFLT3CSF1RFLT1
SCHEMBL3958645 0.86 KDR (0.69) KDRKITFLT3CSF1RFLT1
Hydrochloric Acid SCHEMBL3957832 0.83 KDR (0.49) KDRKITFLT3CSF1RFLT1
SCHEMBL422816 0.82 KDR (0.79) KDRKITFLT3CSF1RFLT1
SCHEMBL3960218 0.81 KDR (0.67) KDRKITFLT3CSF1RFLT1
Hydrochloric Acid SCHEMBL3957794 0.80 KDR (0.66) KDRKITFLT3CSF1RFLT1
SCHEMBL3958687 0.80 KDR (0.61) KDRFLT3
SCHEMBL3960509 0.80 MAP4K4 (0.48) KDRKITFLT3CSF1RFLT1
SCHEMBL3955018 0.79 SGK1 (0.61) KDRKITCSF1RAURKBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517902-B2 Substituted indazoles, compositions containing the same, and the preparation and use thereof AVENTIS PHARMA S.A. (FR) 2009-04-14 US claimed
US-20070161626-A1 Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof AVENTIS PHARMA S.A. (FR) 2007-07-12 US claimed
CN-1980918-A Substituted indazoles, compositions containing them, preparation and use AVENTIS PHARMA SA (FR) 2007-06-13 CN claimed
US-7517902-B2 Substituted indazoles, compositions containing the same, and the preparation and use thereof AVENTIS PHARMA S.A. (FR) 2009-04-14 US disclosed
US-7517902-B2 Substituted indazoles, compositions containing the same, and the preparation and use thereof AVENTIS PHARMA S.A. (FR) 2009-04-14 US disclosed
US-7517902-B2 Substituted indazoles, compositions containing the same, and the preparation and use thereof AVENTIS PHARMA S.A. (FR) 2009-04-14 US disclosed
US-20070161626-A1 Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof AVENTIS PHARMA S.A. (FR) 2007-07-12 US disclosed
US-20070161626-A1 Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof AVENTIS PHARMA S.A. (FR) 2007-07-12 US disclosed
US-20070161626-A1 Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof AVENTIS PHARMA S.A. (FR) 2007-07-12 US disclosed
CN-1980918-A Substituted indazoles, compositions containing them, preparation and use AVENTIS PHARMA SA (FR) 2007-06-13 CN disclosed
EP-1765813-A1 SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, PREPARATION AND USE Aventis Pharma S.A. (FR) 2007-03-28 EP disclosed
WO-2006003276-A1 SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, PREPARATION AND USE AVENTIS PHARMA S.A. (FR) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161626-A1 Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof CYP3A43, CYP3A7, CYP3A5 KDR 4627/4885KIT 870/4885FLT3 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.